French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials. Sumitomo ...

The Jets continue to bolster their safety room this offseason. SNY's Connor Hughes confirms that the Jets are re-signing safety Andre Cisco to a one-year deal. The deal is for $2.5 million but can go ...

In this “Corey Noles speaks with Teradata Global AI Lead Dr. Chris Hillman, who explains that open data and technology ...

Amazon is rolling out one-hour and three-hour delivery in some parts of the U.S. The company is speeding up deliveries even further after investing significant money and resources to make same-day ...

At this bigger-than-ever GTC, Huang made it clear that Nvidia is gunning to command the levers of the entire AI factory ...

You’d be forgiven for thinking the BYD Atto 3 Evo is just a light facelift of the original (which was launched back in 2023). But appearances can be deceiving; it’s been massively overhauled, and BYD ...

Dinesh Karthik will answer your questions ahead of the 4th Test vs. Australia! Send them in using #heyCB on X to be featured in our next episode. * Second highest wicket take for India (537 wickets), ...